Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc (ADAP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ADAP · as of Sep 30, 2025
Ownership Breakdown
57
Institutional Holders
▼ 8 vs Q2
$5.47M
Total Inst. Value
▼ $22.22M vs Q2
258.27M
Shares Outstanding
freeFloat 98.89%
42.10M
13F Shares Held
▼ 73.49M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ADAP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
LONG FOCUS CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 18.58M | 7.03% | 7.03% | $2.42B | Nov 14, 2025 | ▼ 5.18M |
UBS GROUP AG biological products, (no diagnostic substances) | 6.67M | 2.52% | 2.52% | $866.76M | Nov 13, 2025 | ▲ 6.60M |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 4.05M | 1.54% | 1.54% | $527.03M | Nov 13, 2025 | ▲ 2.17M |
MORGAN STANLEY biological products, (no diagnostic substances) | 3.67M | 1.39% | 1.39% | $476.59M | May 27, 2026 | ▼ 566.2K |
JANE STREET GROUP, LLC biological products, (no diagnostic substances) | 2.81M | 1.06% | 1.06% | $364.69M | Nov 14, 2025 | NEW |
ACADIAN ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 1.49M | 56.24% | 56.24% | $186.00M | Nov 13, 2025 | ▼ 479.0K |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 1.32M | 49.97% | 49.97% | $171.56M | Feb 3, 2026 | ▲ 178.0K |
EMPIRICAL FINANCE, LLC biological products, (no diagnostic substances) | 800.0K | 30.29% | 30.29% | $104.00M | Nov 13, 2025 | — held |
B. RILEY WEALTH ADVISORS, INC. biological products, (no diagnostic substances) | 500.0K | 18.93% | 18.93% | $65.00M | Oct 31, 2025 | NEW |
RATHBONES GROUP PLC biological products, (no diagnostic substances) | 432.8K | 16.39% | 16.39% | $56.27M | Nov 13, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
11
Increased
+9.63M shares11
New Positions
first time holders12
Decreased
−6.65M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.98M
+9.63M / −6.65M
Net new holders
+10
11 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ADAP insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
7
Sell transactions
0.00
Buy/Sell ratio
$84M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Adaptimmune Therapeutics plc (ADAP) is primarily owned by institutional investors, who hold approximately 16.3% of total shares outstanding. Company insiders own approximately 1.11%, while retail and public investors account for the remaining 82.59%.
The largest institutional shareholder of Adaptimmune Therapeutics plc is LONG FOCUS CAPITAL MANAGEMENT, LLC, holding approximately 18.58 million shares — equal to 7.03% of outstanding shares — as of September 30, 2025.
A total of 57 institutional investors currently hold ADAP stock, with a combined institutional value of approximately $5,465,824 as of the most recent 13F filing period.
Frequently asked questions
ADAP ownershipAdaptimmune Therapeutics plc (ADAP) is primarily owned by institutional investors, who hold approximately 16.3% of shares. The largest shareholder is LONG FOCUS CAPITAL MANAGEMENT, LLC with a 7.03% stake. Company insiders hold 1.11%. Data sourced from SEC Form 13F as of September 30, 2025.